Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trishul
- Development stage
- Phase 2
- Lead developer
- University of Kelaniya
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trishul is an Ayurvedic medicinal agent being investigated by the University of Kelaniya for its potential anti-neoplastic effects in patients with rectal cancer. As an Ayurvedic formulation, it is derived from traditional medicine practices and is typically administered orally at a dose of 750 mg twice daily. In a clinical trial context, it is evaluated as an adjunct to standard treatment, starting preoperatively and continuing postoperatively, to assess its impact on tumor regression, disease-free survival, and overall survival. While its specific herbal or mineral composition is not detailed in the trial summary, it is categorized as an anti-cancer Ayurvedic drug.
- Brand names
- Trishul
Beyond the preview
Go deeper on Trishul.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trishul.